Sprint Bioscience AB (5JA1) Financial Statements
Sprint Bioscience AB Financial Overview
Sprint Bioscience AB's market cap is currently $34.50M. The company's EPS TTM is $0.72; its P/E ratio is 5.00; Sprint Bioscience AB has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 167.17M | $ 65.64M | $ 50.48M | $ 83.00K | $ 35.11M |
| Gross Profit | $ 97.33M | $ 37.30M | $ 41.79M | $ -60.91M | $ 24.68M |
| Operating Income | $ 97.33M | $ -19.67M | $ -845.00K | $ -60.91M | $ -25.47M |
| EBITDA | $ 98.40M | $ -17.32M | $ 396.00K | $ -60.00M | $ -24.49M |
| Net Income | $ 91.74M | $ -18.28M | $ -438.00K | $ -60.17M | $ -25.35M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 126.70M | $ 25.06M | $ 49.93M | $ 29.49M | $ 70.64M |
| Total Assets | $ 136.66M | $ 42.05M | $ 62.38M | $ 37.42M | $ 79.14M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -126.70M | $ -25.06M | $ -49.93M | $ -29.49M | $ -70.64M |
| Total Liabilities | $ 17.48M | $ 32.78M | $ 34.60M | $ 9.23M | $ 8.68M |
| Stockholders' Equity | $ 119.18M | $ 9.27M | $ 27.77M | $ 28.19M | $ 70.45M |
| Cash Flow | |||||
| Free Cash Flow | $ 83.44M | $ -24.65M | $ 20.42M | $ -59.05M | $ -42.82M |
| Operating Cash Flow | $ 83.53M | $ -23.36M | $ 22.87M | $ -59.05M | $ -40.12M |
| Investing Cash Flow | $ -54.00K | $ -1.30M | $ -2.45M | $ 0.00 | $ -2.71M |
| Financing Cash Flow | $ 18.17M | $ -225.00K | $ 24.00K | $ 17.90M | $ 86.39M |
Currency in SEK